A novel class of powerful and selective hexosaminidase and protein O-GlcNAcase inhibitors: N-modified cyclopentanoid sugar analogs

<none>

Programme Social programme Plenary speakers Keynote speakers 1st EuroCarb Young Researcher (ECYR) Workshop CarboMet Workshop Mini symposium: Glycobiology at the LUMC and beyond Favourites/Agenda

Social programme

Plenary speakers

Keynote speakers

1st EuroCarb Young Researcher (ECYR) Workshop

CarboMet Workshop

Mini symposium: Glycobiology at the LUMC and beyond

Favourites/Agenda

Photos

Venue & Travel Venue Accommodation City of Leiden Travel directions

Venue

Accommodation

City of Leiden

Travel directions

Committees

Home

A novel class of powerful and selective hexosaminidase and protein O-GlcNAcase inhibitors: N-modified cyclopentanoid sugar analogs

Patrick Weber 1 , Arnold E. Stütz 1

1 Glycogroup, Institute of Organic Chemistry, Graz University Of Technology, Graz, Austria

Half of the nearly sixty lysosomal storage diseases described to date are caused by the lack or catalytic incompetence of carbohydrate processing enzymes such as glycosidases, phosphorylases as well as other hydrolases which manipulate sugar moieties. Hexosaminidases as well as O-GlcNAcase are involved in the chemical manipulation or catalytic removal of N-acetyl-D-glucosaminyl or N-acetyl-D-galactosaminyl residues from degradation-bound polysaccharides and glycoconjugates.

Regulation of O-GlcNAcase, which belongs to the family of hexosaminidases, prevents the tau protein from hyperphosphorylation which is a pathological hallmark for diseases such as Alzheimer’s. [1] It has been shown that inhibition of O-GlcNAcase enhances the autophagy in the brain and thus shows a benefit in neurodegenerative diseases such as Parkinson’s. [2] Selective inhibition of O-GlcNAcase can be achieved by elongation of the C-2 substituent to exploit a deep pocket at the active site of the enzyme. [3] In this presentation the synthesis as well as the biological activities of novel and selective cyclopentanoid O-GlcNAcase inhibitors (1) as well as hexosaminidase inhibitors (2) will be presented.

Figure 1: Synthesized O-GlcNAcase and hexosaminidase inhibitors.

Lim, S.; Haque, M.; Nam, G.; Ryoo, N.; Rhim, H.; and Kim, Y. K.; Int. J. Mol. Sci. 2015, 16(9), 20212-20224.

Zhu, Y.; Shan, X.; Safarpur, F.; Go, E. N.; Li, N.; Shan, A.; Huang, M. C.; Deen, M.; Holicek, V.; Shmus, R.; Madden, Z.; Gorski, S.; Silverman, M. A. and Vocadlo D. J.; ACS Chem. Neurosci. 2018, 9, 1366-1379.

Alonso, J.; Schimpl, M. and van Aalten, D. M. F.; J. Biol. Chem. 2014, 289(50), 34433-34439.

Contact eurocarb@eurocarb2019.com for general questions about EUROCARB2019, or codee@eurocarb2019.com for scientific questions.

Leiden University / Leiden Institute of Chemistry lic.leidenuniv.nl

European Carbohydrate Organisation

Congress by Design www.congressbydesign.com